OPTI-FREE Family STUDY
- Conditions
- Contact Lens Care
- Interventions
- Device: OPTI-FREE EXPRESS MPDS and Alcon contact lens caseDevice: OPTI-FREE PureMoist MPDS and Alcon contact lens caseDevice: OPTI-FREE REPLENISH MPDS and Alcon contact lens caseDevice: Habitual contact lenses
- Registration Number
- NCT06592521
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this post-market clinical follow-up (PMCF) study is to evaluate the long-term safety and performance of 3 commercially available contact lens cleaning and disinfecting solutions in a pediatric population. This study will be conducted in Canada and the US.
- Detailed Description
Subjects will participate in the study for approximately 90 days, with telephone calls scheduled on Day 30 ± 7 (Visit 2) and Day 60 ± 7 (Visit 3) and an in-office follow-up visit scheduled on Day 90 ± 7 (Visit 4). Subjects may have unscheduled visits if deemed necessary per the Investigator's judgment.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Subject and parent/legally authorized representative able to understand and sign an IRB approved informed consent/assent form.
- Subject willing to follow and be able to attend all scheduled study visits as required per protocol.
- Successful wear of daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses in both eyes for the past 3 months for a minimum of 5 days per week and 8 hours per day.
- Other protocol-specified inclusion criteria may apply.
Key
- Any ocular disease or condition that would contraindicate contact lens wear.
- Use of systemic or ocular medication that would contraindicate contact lens wear.
- Any known sensitivity to any ingredients in the study products.
- Current or history of pathological dry eye in either eye that would in the opinion of the Investigator preclude contact lens wear.
- Any use of habitual/prescribed topical ocular medication or artificial tear or rewetting drop (habitual) that would require instillation during the study.
- Other protocol-specified exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description OFE MPDS OPTI-FREE EXPRESS MPDS and Alcon contact lens case OPTI-FREE EXPRESS MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation. OFE MPDS Habitual contact lenses OPTI-FREE EXPRESS MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation. OFPM MPDS OPTI-FREE PureMoist MPDS and Alcon contact lens case OPTI-FREE PureMoist MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation. OFPM MPDS Habitual contact lenses OPTI-FREE PureMoist MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation. OFR MPDS OPTI-FREE REPLENISH MPDS and Alcon contact lens case OPTI-FREE REPLENISH MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation. OFR MPDS Habitual contact lenses OPTI-FREE REPLENISH MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
- Primary Outcome Measures
Name Time Method Front surface deposits at Day 90 Day 90 Protein and lipid deposits on the front surface of the contact lens will be assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye. Deposits will be graded on a 5-point scale, with 0 being absent and 4 being severe.
Back surface deposits at Day 90 Day 90 Protein and lipid deposits on the back surface of the contact lens will be assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye. Deposits will be graded on a 5-point scale, with 0 being absent and 4 being severe.
Incidence of corneal infiltrative events Up to Day 90 A corneal infiltrate is a single or group of inflammatory cells in the normally clear cornea. Corneal infiltrative events will be detected by the investigator during an eye exam.
Incidence of microbial keratitis Up to Day 90 Microbial keratitis is a sight-threatening infection of the cornea. Incidences of microbial keratitis will be detected by the investigator during an eye exam.
Incidence of solution induced corneal staining (SICS) Up to Day 90 Corneal staining determined by the investigator to be solution-related will be graded by type (pattern of staining) and area (how much) in each of the 5 corneal regions: central, superior, nasal, inferior, temporal.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Contact Alcon Call Center for Trial Locations
🇺🇸Fort Worth, Texas, United States